van den Besselaar B N, van Klaveren D, Berzenji D, Hoesseini A, Jansen J C, Hardillo J A, Baatenburg de Jong R J, Offerman M P J, Sewnaik A
Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Public Health, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Eur Arch Otorhinolaryngol. 2025 May 24. doi: 10.1007/s00405-025-09462-1.
Patients diagnosed with incurable head and neck squamous cell carcinoma (HNSCC) have a poor prognosis, with a median survival of approximately five months. Physicians often struggle to predict prognosis accurately and tend to overestimate survival. Timely sharing of validated accurate individual information on life expectancy could aid in facilitating better patient counseling. However, this knowledge is lacking. Therefore, the aim of this study is to conduct temporal and external validation of the prognostic model OncologIQ Palliative to assess its accuracy and generalizability.
The validation procedure involved temporal assessment in a retrospective cohort of 355 palliative HNSCC patients from Erasmus MC (2017-2020), followed by external validation in a retrospective cohort of 44 patients from Leiden University Medical Center (2019-2021).The discriminative ability of OncologIQ Palliative was assessed using the C-index and calibration was evaluated through graphical assessment, intercept, and slope.
The temporal cohort had a median follow-up of 115 days, and the external cohort 143 days. The model showed moderate discriminative ability in temporal validation (C-index 0.66) and better discrimination in external validation (C-index 0.71). Reasonable agreement was observed between predicted and observed 6-month and 1-year survival rates, with some deviations from the perfect calibration line.
The validation methods conducted in this study underscored the reliability of OncologIQ Palliative. They showed adequate calibration and discrimination in both validation procedures, thereby facilitating the provision of more accurate prognostic counselling for head and neck cancer patients in the palliative phase.
被诊断为无法治愈的头颈部鳞状细胞癌(HNSCC)的患者预后较差,中位生存期约为五个月。医生常常难以准确预测预后,且往往高估生存期。及时分享经过验证的准确的个体预期寿命信息有助于更好地为患者提供咨询。然而,目前缺乏这方面的知识。因此,本研究的目的是对OncologIQ Palliative预后模型进行时间和外部验证,以评估其准确性和可推广性。
验证过程包括对伊拉斯姆斯医学中心(2017 - 2020年)355例姑息治疗的HNSCC患者的回顾性队列进行时间评估,随后对莱顿大学医学中心(2019 - 2021年)44例患者的回顾性队列进行外部验证。使用C指数评估OncologIQ Palliative的鉴别能力,并通过图形评估、截距和斜率评估校准情况。
时间队列的中位随访时间为115天,外部队列的中位随访时间为143天。该模型在时间验证中显示出中等鉴别能力(C指数为0.66),在外部验证中鉴别能力更好(C指数为0.71)。观察到预测的和实际的6个月及1年生存率之间有合理的一致性,但与完美校准线存在一些偏差。
本研究中进行的验证方法强调了OncologIQ Palliative的可靠性。它们在两个验证过程中均显示出足够的校准和鉴别能力,从而有助于为姑息治疗阶段的头颈癌患者提供更准确的预后咨询。